GIFT is a pilot, randomized, double-blinded clinical trial that will examine the effects of
unacylated ghrelin on walking ability in people with peripheral artery disease (PAD) compared
to placebo. Preliminary evidence suggests that unacylated ghrelin may improve blood flow to
the extremities and promote improved skeletal muscle growth and energy use.
A total of 30 participants with PAD will be randomized to one of two groups: unacylated
ghrelin injections or placebo injections . Participants will self-administer the study drug
or placebo subcutaneously once daily for four months. The primary outcome is change in
six-minute walk distance between baseline and 4-month follow-up